| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802561201012 | 256120101 | PRAVALONG TAB 20MG/TAB BTx14 (BLIST 2x7) | 2.93 | 03.07 | 4.23 |
| 05/2018 | 2802561201029 | 256120102 | PRAVALONG TAB 20MG/TAB BTx28 (BLIST 4x7) | 4.49 | 4.71 | 6.49 |
| 05/2018 | 2802561202019 | 256120201 | PRAVALONG TAB 40MG/TAB BTx14 (BLIST 2x7) | 3.84 | 04.03 | 5.55 |
| 05/2018 | 2802561202026 | 256120202 | PRAVALONG TAB 40MG/TAB BTx28 (BLIST 4x7) | 6.77 | 7.10 | 9.78 |
For the treatment of hypercholesterolemia to reduce the risk of myocardial infarction.
Like lovastatin and simvastatin, pravastatin inhibits hydroxymethylglutaryl-CoA (HMG-CoA) reductase. As HMG-CoA is necessary for the intracellular synthesis of cholesterol, its inhibition results in increased clearance of circulating LDL. Pravastatin also inhibits hepatic synthesis of VLDL, the precursor for LDL, reducing circulating cholesterol and LDL cholesterol.
Rhabdomyolysis; LD<sub>50</sub>=mg/kg (orally in rat)
Average oral absorption of pravastatin is 34% and absolute bioavailability is 17%.
77 hours
Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces.